ASMB
Assembly Biosciences, Inc.NASDAQHealthcare$29.01-1.43%ClosedMarket Cap: $460.2M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.58
P/S
6.41
EV/EBITDA
-39.57
DCF Value
$-64.83
FCF Yield
-8.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.7%
Operating Margin
-16.8%
Net Margin
-8.5%
ROE
-5.6%
ROA
-2.4%
ROIC
-5.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $42.5M | 99.9% | $19.8M | $22.1M | $2.49 | — |
| FY 2025 | $72.3M | 99.8% | $-12.1M | $-6.1M | $-0.55 | — |
| Q3 2025 | $10.8M | 100.0% | $-10.9M | $-9.2M | $-1.20 | — |
| Q2 2025 | $9.6M | -67.5% | $-11.1M | $-10.2M | $-1.33 | — |
| Q1 2025 | $9.4M | 100.0% | $-9.9M | $-8.8M | $-1.17 | — |
| Q4 2024 | $7.4M | -94.1% | $-11.5M | $-10.3M | $-1.72 | — |
| FY 2024 | $28.5M | 100.0% | $-45.4M | $-40.2M | $-6.69 | — |
| Q3 2024 | $6.8M | 100.0% | $-11.0M | $-9.6M | $-1.51 | — |
| Q2 2024 | $8.5M | 99.6% | $-12.2M | $-11.2M | $-1.98 | — |
| Q1 2024 | $5.8M | 99.4% | $-10.7M | $-9.1M | $-1.66 | — |
| Q4 2023 | $7.2M | 98.8% | $-12.6M | $-11.0M | $-2.00 | — |
| FY 2023 | $7.2M | -582.7% | $-64.6M | $-61.2M | $-13.38 | — |